It is important to consider cardiovascular (CV) risk when selecting patients in which to use tyrosine kinase inhibitors (TKIs), according to a study involving more than 1,600 individuals.
Participants were adults with chronic myelogenous leukemia (CML). Investigators looked at CV conditions and risk factors at baseline and 5 years later. Among the results:
- At 5 years, CV conditions were present in one-third of patients.
- CV risk factors were present in 78%.
- CML patients were 1.3 to 3.5 times more likely to have CV conditions compared with the general population.
- They were 20% to 40% more likely to develop hypertension, diabetes, and obesity.
- CV risk factor prevalence was not different between CML patients and the general population who lived in the US Stroke Belt.
The authors noted that their findings underscore the importance of following guidelines, suggesting that CV risk be considered when selecting TKIs.
Coutinho A, Makenbaeva D, Farrelly E, Landsan-Blumberg P, Lenihan D. Elevated cardiovascular disease risk in patients with chronic myelogenous leukemia seen in community-based oncology practices in the United States. [Published online ahead of print June 16, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.06.011.
This Week's Must Reads
Must Reads in CML
Treatment-free remission in CML, Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.
Bosulif Approved to Treat Newly-Diagnosed Ph+ CML, Avillion news release; 2017 Dec 19
Sprycel Approved for Children with Ph+ CML, FDA news release; 2017 Nov 9
Be Sure to Consider This When Selecting TKIs, Clin Lymphoma Myeloma Leuk; ePub 2017 Jun 16; Coutinho, et al